AKT (Ser473)(9H11) Monoclonal Antibody, PE-Cy5.5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bsm-33281M-PE-Cy5.5-100uL |
| Product Name | AKT (Ser473)(9H11) Monoclonal Antibody, PE-Cy5.5 Conjugated |
| Applications |
WB
|
| Reactivity | Human, Mouse, Rat, Others |
| Specifications | |
| Conjugation | PE-Cy5.5 |
| Host | Mouse |
| Source | KLH conjugated Synthesised phosphopeptide derived from human AKT around the phosphorylation site of Ser473 |
| Modification Site | Ser473 |
| Clonality | Monoclonal |
| Clone # | 9H11 |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein G. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 207 |
| Swiss Prot | O57513 |
| Synonyms | Akt(Phospho-Ser473); AKT (phospho-S473); AKT (phospho Ser473); p-AKT (Ser473); AKT 1; AKT; AKT1; AKT-1; AKT1_HUMAN; C AKT; cAKT; MGC9965; MGC99656; Oncogene AKT1; PKB; PKB alpha; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene c-Akt; RAC Alpha; RAC alpha serine/threonine protein kinase; RAC; RAC PK Alpha; Rac protein kinase alpha; RAC Serine/Threonine Protein Kinase; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; v akt murine thymoma viral oncogene homolog 1; vAKT Murine Thymoma Viral Oncogene Homolog 1. |
| Background | The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2011] |
| Application Dilution | |
| WB | 1:300-5000 |
Frequently asked questions
Which applications is AKT (Ser473)(9H11) Monoclonal Antibody, PE-Cy5.5 Conjugated (BSM-33281M-PE-CY5-5) validated for, and at what dilution?
BSM-33281M-PE-CY5-5 is validated for WB (1:300-5000). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does AKT (Ser473)(9H11) Monoclonal Antibody, PE-Cy5.5 Conjugated (BSM-33281M-PE-CY5-5) react with?
Tested reactivity: Human, Mouse, Rat, Others.
How should BSM-33281M-PE-CY5-5 be stored?
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
What immunogen was used to raise AKT (Ser473)(9H11) Monoclonal Antibody, PE-Cy5.5 Conjugated (BSM-33281M-PE-CY5-5)?
KLH conjugated Synthesised phosphopeptide derived from human AKT around the phosphorylation site of Ser473
What are the excitation and emission wavelengths of the PE-Cy5.5 conjugate (BSM-33281M-PE-CY5-5)?
PE-Cy5.5 on BSM-33281M-PE-CY5-5: excitation / emission 488nm/694nm.